SCHEMBL538530

SCHEMBL538530

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CI)[C@@H](O)[C@H]1O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHCY P23526 8/20 0.80
NADK O95544 1/20 0.80
ADORA3 P0DMS8 2/20 0.80
DOT1L Q8TEK3 2/20 0.80
DPP4 P27487 1/20 0.80
MEN1 O00255 1/20 0.80
SLC28A1 O00337 1/20 0.80
MAP3K7 O43318 1/20 0.80
SLC28A2 O43868 1/20 0.80
GAPDH P04406 1/20 0.80
MAPK1 P28482 1/20 0.80
ADORA2A P29274 1/20 0.80
ADORA2B P29275 1/20 0.80
ADORA1 P30542 1/20 0.80
STAT6 P42226 1/20 0.80
PI4KA P42356 1/20 0.80
KMT2A Q03164 1/20 0.80
SMN1; SMN2 Q16637 1/20 0.80
PI4K2B Q8TCG2 1/20 0.80
SLC29A1 Q99808 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6297859 1.00 AHCY (0.80) AHCYNADKADORA3DOT1LDPP4
SCHEMBL538531 1.00 AHCY (0.80) AHCYNADKADORA3DOT1LDPP4
SCHEMBL16057823 0.90 ADORA1 (0.80) AHCYNADKADORA3DOT1LDPP4
SCHEMBL784361 0.89 AHCY (0.65) AHCYNADKADORA3DOT1LDPP4
Adenosine SCHEMBL23420216 0.89 ADORA3 (1.00) AHCYNADKADORA3DOT1LDPP4
Adenosine SCHEMBL406207 0.89 ADORA3 (1.00) AHCYNADKADORA3DOT1LDPP4
Adenosine SCHEMBL23804425 0.89 ADORA3 (1.00) AHCYNADKADORA3DOT1LDPP4
Adenosine SCHEMBL2228590 0.89 ADORA3 (1.00) AHCYNADKADORA3DOT1LDPP4
Adenosine SCHEMBL1821276 0.89 ADORA3 (1.00) AHCYNADKADORA3DOT1LDPP4
SCHEMBL506314 0.89 DOT1L (0.81) AHCYNADKADORA3DOT1LDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160125-A1 Compositions and methods for nonenzymatic ligation of oligonucleotides and detection of genetic polymorphisms UNIVERSITY OF ROCHESTER (US) 2006-07-20 US claimed
JP-2002515885-A 2002-05-28 JP claimed
EP-0880353-A4 COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION THERASYS INC (US) 2001-04-18 EP claimed
US-5998423-A IN SKIN OR HAIR; ADMINISTERING ADENOSINE RECEPTOR ANTAGONIST THERASYS, INC. (US) 1999-12-07 US claimed
EP-0880353-A1 COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION Therasys, Inc. (US) 1998-12-02 EP claimed
WO-1998015276-A1 COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION THERASYS, INC. (US) 1998-04-16 WO claimed
CN-121678872-A Method for detecting iodo-nucleoside in drinking water by solid phase extraction-vacuum centrifugal concentration-liquid chromatography tandem mass spectrometry 浙江大学 2026-03-17 CN disclosed
US-20230017490-A1 STING INHIBITORS AND THEIR THERAPEUTIC USES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-01-19 US disclosed
EP-2677039-B1 Detection of nucleic acid targets using chemically reactive oligonucleotide probes DXTERITY DIAGNOSTICS (US) 2022-08-17 EP disclosed
US-10829803-B2 Detection of nucleic acid targets using chemically reactive oligonucleotide probes DXTERITY DIAGNOSTICS INCORPORATED (US) 2020-11-10 US disclosed
US-20190106739-A1 CHEMICAL LIGATION DEPENDENT PROBE AMPLIFICATION (CLPA) DXTERITY DIAGNOSTICS INCORPORATED 2019-04-11 US disclosed
US-10066257-B2 Methods and compositions for detecting target nucleic acids DXTERITY DIAGNOSTICS INCORPORATED (US) 2018-09-04 US disclosed
EP-1928475-B1 ANTIVIRAL PHOSPHORAMIDATES OF 4'-C-AZIDO-SUBSTITUTED PRONUCLEOTIDES RIBOSCIENCE LLC (US) 2018-05-23 EP disclosed
US-5213972-A Production of thymidine and deoxyuridine, intermediates for AZT CHEMGEN CORPORATION (US) 1993-05-25 US disclosed
WO-1992020816-A1 DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF YALE UNIVERSITY (US) 1992-11-26 WO disclosed
EP-0457326-A1 Antiviral agents SYNTEX (U.S.A.) INC. (US) 1991-11-21 EP disclosed
EP-0425680-A1 NEW VITAMIN B 12? DERIVATIVE, PRODUCTION THEREOF, AND APPLICATION THEREOF TEIJIN LIMITED (JP) 1991-05-08 EP disclosed
EP-0126394-B1 ENZYMATIC REMOVAL OF AROMATIC HYDROXY COMPOUNDS AND AROMATIC AMINES FROM WASTE WATERS PHILLIPS PETROLEUM COMPANY (US) 1987-10-28 EP disclosed
EP-0126394-A1 Enzymatic removal of aromatic hydroxy compounds and aromatic amines from waste waters PHILLIPS PETROLEUM COMPANY (US) 1984-11-28 EP disclosed
US-4485016-A Enzymatic removal of aromatic hydroxy compounds and aromatic amines from waste waters PHILLIPS PETROLEUM COMPANY (US) 1984-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230017490-A1 STING INHIBITORS AND THEIR THERAPEUTIC USES STING1, CGAS, MAVS AHCY 3830/4885NADK 1738/4885ADORA3 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.